Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY Score: using intraprostatic (68)Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63:1644–50.

CAS  PubMed  PubMed Central  Google Scholar 

Mazzone E, Cannoletta D, Quarta L, Chen DC, Thomson A, Barletta F, et al. A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol. 2025;87:654–71.

Article  CAS  PubMed  Google Scholar 

Li B, Duan L, Shi J, Han Y, Wei W, Cheng X, et al. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy. Front Oncol. 2022;12:1072437.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buteau JP, Moon D, Fahey MT, Roberts MJ, Thompson J, Murphy DG, et al. Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [(68)Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. Eur Urol Oncol. 2024;7:544–52.

Article  PubMed  Google Scholar 

Wang Q, Ketteler S, Bagheri S, Ebrahimifard A, Luster M, Librizzi D, et al. Diagnostic efficacy of [(99m)Tc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis. BMC Cancer. 2024;24:982.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farkas I, Sipka G, Bakos A, Maráz A, Bajory Z, Mikó Z, et al. Diagnostic value of [(99m)Tc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer. Ther Adv Med Oncol. 2024;16:17588359231221342.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jonmarker O, Sunderland M, Steffens L, Samuelsson C, O’Keeffe D, Puri J, et al. Retrospective analysis of [ 99m Tc]Tc-HYNIC-PSMA single photon emission computed tomography CT in patients with prostate cancer. Nucl Med Commun. 2026;47:41–8.

Article  CAS  PubMed  Google Scholar 

Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020;10:45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aryana K, Aghaee A, Askari E, Fakhar Y, Raeisi N, Mottaghi M, et al. Comparison of (99m)Tc-HYNIC-PSMA-11, bone scan and post radioligand therapy images in mCRPC patients: A single center experience. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2025;44:500157.

CAS  PubMed  Google Scholar 

RoshanRavan V, Ghorbani H, Soltani S, Shabani E, Tanha H, Moradi A, et al. The diagnostic value of whole-body HYNIC-PSMA 11 -Tc [(99 m)Tc] SPECT/CT scan in early staging of patients with moderate- and high-risk prostate cancer. Ann Nucl Med. 2025;39:833–46.

Article  CAS  PubMed  Google Scholar 

Tayal S, Sinha R, Shukla V, Venkatachalam MM, Suresh A, Kumar JP, et al. Biodistribution and semiquantitative analysis of (99m)Tc-HYNIC-PSMA-11in prostate cancer patients: a retrospective study. Indian J Nucl Med. 2025;40:269–77.

Article  PubMed  PubMed Central  Google Scholar 

Vats K, Agrawal K, Sharma R, Sarma HD, Satpati D, Dash A. Preparation and clinical translation of (99m)Tc-PSMA-11 for SPECT imaging of prostate cancer. Medchemcomm. 2019;10:2111–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, et al. Head-to-head comparison of (99m)Tc-PSMA and (99m)Tc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial. Sci Rep. 2022;12:15993.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agrawal K, Patro PSS, Singhal T, Satpati D, Nayak P, Mandal S, et al. Diagnostic performance of (99m)Tc-PSMA SPECT/CT in primary prostate carcinoma. World J Clin Cases. 2025;13:107555.

Article  PubMed  PubMed Central  Google Scholar 

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469–78.

Article  PubMed  Google Scholar 

Zhang J, Kang F, Gao J, Jiao J, Quan Z, Ma S, et al. A prostate-specific membrane antigen pet-based approach for improved diagnosis of prostate cancer in gleason grade group 1: a multicenter retrospective study. J Nucl Med. 2023;64:1750–7.

Article  CAS  PubMed  Google Scholar 

Kwan TN, Spremo S, Teh AYM, McHarg D, Thangasamy I, Woo HH. Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer. Prostate Int. 2021;9:107–12.

Article  PubMed  Google Scholar 

Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, et al. Response assessment and prediction of progression-free survival by 68Ga-PSMA-11 PET/CT based on Tumor-to-Liver Ratio (TLR) in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy. Biomolecules. 2021;11:1099.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Groener D, Schneider S, Baumgarten J, Happel C, Klimek K, Mader N, et al. Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 radioligand therapy: value of psma-uptake thresholds in predicting targetable lesions. Cancers. 2023;15:473.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidkonz C, Götz TI, Atzinger A, Ritt P, Prante O, Kuwert T, et al. 99mTc-MIP-1404 SPECT/CT for assessment of whole-body tumor burden and treatment response in patients with biochemical recurrence of prostate cancer. Clin Nucl Med. 2020;45:e349–57.

Article  PubMed  Google Scholar 

Ruan X, Gao Y. Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024;43:500054.

CAS  PubMed  Google Scholar 

Liepe K, Hoang TM, Baehr M. The diagnostic accuracy of [99mTc]Tc-PSMA SPECT/CT for recurrent prostate cancer based on individual patient attributes. Eur J Nucl Med Mol Imaging. 2026;53:2245–56. https://doi.org/10.1007/s00259-025-07630-3.

Harsini S, Fallahi B, Karamzade Ziarati N, Razi A, Amini E, Emami-Ardekani A, et al. A prospective study on [(68)Ga]-PSMA PET/CT imaging in newly diagnosed intermediate- and high-risk prostate cancer. Asia Ocean J Nucl Med Biol. 2021;9:101–10.

PubMed  PubMed Central  Google Scholar 

Takahashi H, Nakai H, Ballman KV, Lomas DJ, Mynderse LA, Kawashima A, et al. Localization of PSMA-avid lesions on PSMA PET-CT on prostate MRI in patients with PI-RADS 3. Abdom Radiol (NY). 2025;50:5948–62.

Article  PubMed  Google Scholar 

Uslu H, Şahin D, İbişoğlu E, Tatoğlu MT. PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillance. Ann Nucl Med. 2025;39:334–41.

Article  PubMed  Google Scholar 

Chen DC, Buteau JP, Emmett L, Alipour R, de Galiza Barbosa F, Roberts MJ, et al. Prevalence and medium-term outcomes of patients with biopsy-proven intermediate- to high-risk prostate adenocarcinoma with low intraprostatic uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA study. J Nucl Med. 2025;66:713–8.

Article  CAS  PubMed  Google Scholar 

Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, et al. Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int. 2019;124(Suppl 1):42–9.

Article  CAS  PubMed  Google Scholar 

Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, et al. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int. 2020;125:515–24.

Article  CAS  PubMed  Google Scholar 

Jishen Z, Yujie X, Ting Y, Ju J, Zhaohui H. Value of prostate-specific membrane antigen PET/CT in reducing unnecessary prostate biopsies in prostate cancer. J Sun Yat-sen Univ (Medical Sci Edition). 2025;46:311–7.

Google Scholar 

Zhang F, Li X, Zhang J, Quan Z, Zhang Z, Han T, et al. Performance of PRIMARY Score based on PSMA-PET imaging in suspected prostate cancer patients with different PSA ranges: a retrospective study. Am J Nucl Med Mol Imaging. 2025;15:200–7.

Article  PubMed  PubMed Central